Javid Moslehi is a Cardiology physician affiliated with University of California, San Francisco. OpenAlex indexes 487 publications with 43,651 citations (h-index 97). By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
555 Mission Bay Blvd, South
San Francisco, CA 94143
Telephone
415-353-3109Provider last certified this registry record 24 Jan 2023.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Sumitomo Pharma America, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
83.3%Beta blocker48.7%Metoprolol Succinate100%Part D≥14 patientsCalcium channel blocker20.5%Amlodipine Besylate100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
16.7%Alkaloid16.7%Colchicine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2025 per NIH RePORTER. The latest:
- Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
University of California, San Francisco
FY2025$615,145R01HL155990 - Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
University of California, San Francisco
FY2024$606,001R01HL155990 - Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension
University of California, San Francisco
FY2023$646,539R01HL141466
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune-checkpoint inhibitors: long-term implications of toxicity
Nature Reviews Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Emmanuelle Waubant, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Peter Hunt, MD
University of California, San Francisco
Owen Wolkowitz, MD
University of California, San Francisco
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”